David J. Andorsky, MD, discusses the findings from a subgroup analysis of patients with relapsed/refractory indolent non-Hodgkin lymphoma over the age of 70 in the phase 3b MAGNIFY clinical trial.
Videos
Maha Hussain, MD, discusses the current role of PARP inhibitors in the treatment landscape of prostate cancers and where she sees this therapeutic approach evolving in the coming years.
Anne Chiang, MD, associate professor, Medical Oncology, Yale School of Medicine, discusses key takeaways on a presentation around managing non–small cell lung cancer cases in patients with contralateral lung nodules and dominant tumors.
Mehmet K. Samur, PhD, discusses findings from an analysis evaluating high-dose melphalan followed by autologous stem cell transplant as treatment of patients with multiple myeloma compared with the standard of care treatment regimen lenalidomide, bortezomib, and dexamethasone alone.
Neal D. Shore, MD, FACS, discusses the current treatment landscape and upcoming drugs being reviewed by the FDA for the treatment of patients with bladder cancer.
Andrew M. Brunner, MD, shares his key take home message from a phase 1b clinical trial investigating sabatolimab as treatment of patients with acute myeloid leukemia, as well as high-risk myelodysplastic syndrome.
Justin M. Watts, MD, discusses the key takeaway from the phase 2 Study P-2001 clinical trial, a randomized study comparing the safety and efficacy of pevonedistat in combination with azacitidine in patients with high-risk myelodysplastic syndromes.
Key opinion leaders close the discussion by providing insight into their respective protocols for acute graft-vs-host (GVHD) disease prophylaxis.
A discussion on upcoming clinical trial data presentations featured at the American Society of Hematology (ASH) 2020 Annual Meeting.
Deepu Madduri, MD, details the efficacy data from the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma.
Expert physicians consider how ongoing developments will impact the treatment paradigm of graft-vs-host disease.
Considerations regarding current clinical practice patterns for transplant-ineligible myeloma and the uptake of newer data by health care professionals.
Deepu Madduri, MD, details the efficacy data from the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma.
Key opinion leaders provide community oncologists with advice for implementing the REACH2 regimen to manage patients with acute graft-vs-host disease (GVHD).
A review of the favorable safety data from CARTITUDE-1 for relapsed/refractory multiple myeloma.
A discussion on decision factors for switching to and deciding upon a second-line therapy, and an overview of the phase 3 REACH2 study with ruxolitinib for glucocorticoid-refractory acute graft-vs-host disease (GVHD).
Hematologist Rafael Fonseca comments on data demonstrated by the PEGASUS study in transplant-ineligible multiple myeloma and expectations for treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone vs other options moving forward.
Clinical updates from the phase 1b/2 CARTITUDE-1 study of ciltacabtagene autoleucel (cilta-cel) for relapsed/refractory multiple myeloma.
Insight regarding the assessment of minimal residual disease in patients with multiple myeloma and using testing results to aid in treatment selection.
Key opinion leaders discuss treatment goals for frontline therapy in patients with acute graft-vs-host disease.
Rationale regarding the use of BCMA-targeted CAR T-cell therapy in relapsed/refractory multiple myeloma.
Expert physicians discuss the role and efficacy of JAK inhibitors in steroid-refractory graft-vs-host disease (GVHD).
Considerations for adding daratumumab to the combination of lenalidomide and dexamethasone to treat transplant-ineligible newly diagnosed multiple myeloma based on updated efficacy data from the phase 3 MAIA trial.
Mayo Clinic’s Rafael Fonseca, MD, comments on the benefits of newer therapies that are now available for patients with newly diagnosed transplant-ineligible multiple myeloma.
A discussion on the role on Janus kinase signaling in the pathogenesis of acute and chronic graft-vs-host disease (GVHD).
Deepu Madduri, MD, provides an overview of the treatment landscape for patients with triple-class refractory multiple myeloma.
Implications for assessing MRD status in patients with transplant-ineligible myeloma and treating appropriate patients with the combination of daratumumab, lenalidomide, and dexamethasone.
Recent updates from the ASH 2020 annual meeting on the phase 1b/2 CARTITUDE-1 trial for relapsed/refractory multiple myeloma.
Expert physicians discuss the rationale behind the clinical use of JAK inhibitors in acute GvHD (graft-versus-host disease), and provide an overview of recent clinical trial data for this treatment approach.
Deepu Madduri, MD, discusses how chimeric antigen receptor T-cell therapy is used for patients with multiple myeloma.